Ukall60 Trial
The UKALL60+ trial is a multi-centre, prospective, non-randomised, multiple pathway trial to document the safety, tolerability and efficacy of standard ‘backbone’ chemotherapeutic regimens in older patients with de novo ALL. Samples will be collected throughout the trial and sent to the central lab (Adult MRD lab at UCL CI) as follow: 1. At diagnosis (pre trial registration) 2. After Phase 1 Induction 3. After Phase 2 Induction 4. a) After Intensification (for patients on the pathway B ONLY) b) After Consolidation 1 (Pathways A, C & D) An additional bone marrow or peripheral blood sample is also sent to the MRD lab if the patient relapses. This sample should be from the routine sample taken to diagnose relapse.
Contact Information
- Email:
- ctc.ukall60@ucl.ac.uk
- Address:
-
CR UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England
Annual Statistics
Year | Access Requests Received | Access Requests Approved | ||||
---|---|---|---|---|---|---|
Internal | External | Commercial | Internal | External | Commercial | |
2015 | N/A | N/A | N/A | N/A | N/A | N/A |
2016 | N/A | N/A | N/A | N/A | N/A | N/A |
2017 | N/A | N/A | N/A | N/A | N/A | N/A |
2018 | N/A | N/A | N/A | N/A | N/A | N/A |
2019 | N/A | N/A | N/A | N/A | N/A | N/A |
2020 | N/A | N/A | N/A | N/A | N/A | N/A |
2021 | N/A | N/A | N/A | N/A | N/A | N/A |
2022 | N/A | N/A | N/A | N/A | N/A | N/A |
2023 | N/A | N/A | N/A | N/A | N/A | N/A |
2024 | N/A | N/A | N/A | N/A | N/A | N/A |